Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting

Beta-glucans, naturally occurring polysaccharides derived from fungi, yeasts, cereals, and bacteria, have emerged as potent cancer therapeutics due to their multifaceted immunomodulatory, anti-inflammatory, and direct anti-tumor properties. These compounds engage pattern recognition receptors (PRRs) such as Dectin-1, Toll-like receptors (TLRs), and complement receptor 3 (CR3), activating macrophages, natural killer (NK) cells, and dendritic cells to enhance anti-tumor immunity. Beta-glucans suppress pro-inflammatory cytokines (e.g., TNF-α, IL-6) and tumor-promoting pathways like NF-κB, while modulating gut microbiota to create an anti-cancer environment. Their nanoparticle formulations enable targeted drug delivery, enhancing the efficacy of chemotherapy and immunotherapy. Clinical studies demonstrate their synergy with cancer treatments, improving patient outcomes and quality of life.